PubRank

Krista K Bowman

Author PubWeight™ 18.20‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell 2009 4.47
2 Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc Natl Acad Sci U S A 2012 3.21
3 Oncogenic ERBB3 mutations in human cancers. Cancer Cell 2013 2.06
4 The crystal structure of the catalytic domain of the NF-κB inducing kinase reveals a narrow but flexible active site. Structure 2012 1.57
5 Structural studies of neuropilin/antibody complexes provide insights into semaphorin and VEGF binding. EMBO J 2007 1.43
6 Molecular basis of Tank-binding kinase 1 activation by transautophosphorylation. Proc Natl Acad Sci U S A 2012 1.40
7 Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers. Proc Natl Acad Sci U S A 2012 1.22
8 Potent, selective, and orally bioavailable inhibitors of mammalian target of rapamycin (mTOR) kinase based on a quaternary substituted dihydrofuropyrimidine. J Med Chem 2011 0.84
9 Potent, selective, and orally bioavailable inhibitors of the mammalian target of rapamycin kinase domain exhibiting single agent antiproliferative activity. J Med Chem 2012 0.84
10 Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT). Bioorg Med Chem Lett 2013 0.81
11 Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study. J Med Chem 2015 0.76
12 Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor. J Med Chem 2016 0.75
13 Correction to Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study. J Med Chem 2016 0.75